Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 9, 2000 - Issue 6
Submit an article Journal homepage
167
Views
17
CrossRef citations to date
0
Altmetric
Review

Recombinant antibodies: a novel approach to cancer diagnosis and therapy

Peter J Hudson CRC for Diagnostic Technologies, CSIRO Health Sciences and Nutrition, 343 Royal Parade, Parkville, Victoria, Australia 3052. [email protected]
Pages 1231-1242 | Published online: 24 Feb 2005

Bibliography

  • BREEDVELD FC: Therapeutic monoclonal antiboclies. Lancet (2000) 355:735-740. BREEDVELD FC: Therapeutic monoclonal antiboclies. Lancet (2000) 355:735–740.
  • WEINER LM: Monoclonal antibody therapy of cancer. Semin. Oncol. (1999) 26:43–51.
  • HUDSON PJ: Recombinant antibody constructs incancer therapy. Curr. Opin. Immunol. (1999) 11:548-557. HUDSON PJ: Recombinant antibody constructs in cancer therapy. Curr. Opin. Immunol. (1999) 11:548–557.
  • GOPAL AK, PRESS OW: Clinical applications of anti-CD20 antibodies. J. Lab. Clin. Med. (1999) 134:445–450.
  • GRILLO-LOPEZ AJ, WHITE CA, VARNS C et al.: Overviewof the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma. Semin. Oncol. (1999) 5:66–73.
  • GOLDENBERG MM: Trastuzumab, a recombinantDNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin. Ther. (1999) 21:309–318.
  • FRIEND PJ, HALE G, CHATENOUD L etai.: Phase I study ofan engineered aglycosylated humanized CD3 antibody in renal transplant rejection. Transplantation (1999) 68:1632–1637.
  • BRADBURY A: Display technologies expand theirhorizons. Trends. Biotechnol. (1999) 17:137–138.
  • MUTUBERRLk R, HOOGENBOOM HR, VAN DER LINDEN E et al.: Model systems to study the parameters determining the success of phage antibody selections on complex antigens. J. Immunol. Methods (1999) 231:65–81.
  • ••The review provides an excellent description about thestrategies for phage display and selection as well as providing details about the current in-vogue methods and troubleshooting.
  • FORRER P, JUNG S, PLUCKTHUN A: Beyond binding:using phage display to select for structure, folding and enzymatic activity in proteins. Curr. Opin. Struct. Biol. (1999) 9:514–520.
  • DE HAARD HJ, VAN NEER N, REURS A et al.: A large non-immunized human fab fragment phage library that permits rapid isolation and kinetic analysis of high affinity antibodies./ Biol. Chem. (1999) 274:18218–18230.
  • ••Probably the largest naïve Fab library constructed to date.Refer to Websites following reference list for descriptions of other antibody libraries that are commercially available.
  • RIDGWAY JB, NG E, KERN JA et al.: Identification of a human anti-CD55 single-chain Fv by subtractive panning of a phage library using tumor and nontumor cell lines. Cancer Res. (1999) 59:2718–2723.
  • COLCHER D, GOEL A, PAVLINKOVA G et al.: Effects of genetic engineering on the pharmacokinetics of antibodies. Q. J. Nucl. Med. (1999) 43:132–139.
  • ••An excellent review describing the practical limitations oflarge 150 kDa IgGs leading to a slow clearance from the blood pool and poor diffusion from the vasculature into and through the tumour. In addition, this paper reviews antibody valency, critical for the functional affinity of an antibody to a cell surface or a polymeric antigen.
  • PARK JM, YANG X, PARKE, PRESS OW, PRESS MF: Assess-ment of novel anti-p185HER-2 monoclonal antibodies for internalization-dependent therapies. Hybridoma (1999) 18:487–495.
  • CRAGG MS, FRENCH RR, GLENNIE MJ: Signaling antibodies in cancer therapy. Curr. Opin. Immunol. (1999) 11:541–547.
  • GHETIE MA, GHETIE V, VITETTA ES: Anti-CD19 antibodies inhibit the function of the P-gp pump in multidrug-resistant B lymphoma cells. Clin. Cancer Res. (1999) 5:3920–3927.
  • HUDSON PJ, KORTT AA: High avidity scEv multimers; diaboclies and triabodies. J. Immunol. Methods (1999) 231:177–190.
  • PAVLINKOVA G, BOOTH BJ, BATRA SK, COLCHER D: Radioimmunotherapy of human colon cancer xenografts using a dimeric single-chain Fv antibody construct. Clin. Cancer Res. (1999) 5:2613–2619.
  • BERESFORD GW, PAVLINKOVA G, BOOTH BJ, BATRA SK,COLCHER D: Binding characteristics and tumor targeting of a covalently linked divalent CC49 single-chain antibody. Int. J. Cancer (1999) 81:911–917.
  • ADAMS GP, SCHIER R: Generating improved single-chain Fv molecules for tumor targeting. J. Immunol. Methods (1999) 231:249–260.
  • VITT F, TARLI L, GIOVANNONI L, ZARDI L, NERI D:Increased binding affinity and valence of recombinant antibody fragments lead to improved targeting of tumoral angiogenesis. Cancer Res. (1999) 59:347–352.
  • WU AM, WILLIAMS LE, ZIERAN L et al.: Anti-carcinoembryonic antigen (CEA) diabody for rapid tumor targeting and imaging. Tumour Targeting (1999) 4:47–54.
  • CASEY JL, PEDLEY RB, KING DJ, GREEN AJ, YARRANTON GT, BEGENT RHJ: Dosimetric evaluation and radioim-munotherapy of anti-tumour multivalent Fab fragments. Br. J. Cancer (1999) 81:972–980.
  • ATWELL J, BREHENEY KA, LAWRENCE LJ, MCCOY AJ, KORTT AA, HUDSON PJ: ScEv Muhimers: Length of the linker between Vii and VI, domains dictates precisely the transition between diabodies and triabodies. Protein Engineering (1999) 12:101–108.
  • ••This publication provides the first detailed description of thediabody/triabody transition and explains why scFv trimers are the preferred conformation when very short polypeptide linkers between V-domains prevent diabody formation.
  • LE GALL F, KIPRIYANOV SM, MOLDENHAUER G, LITTLE M:Di-, tri- and tetrameric single chain Fv antibody fragments against human CD19: effect of valency on cell binding. FESS Lett. (1999) 453:164–168.
  • PAVLINKOVA G, BERESFORD G, BOOTH BJ, BATRA SK,COLCHER D: Charge-modified single chain antibody constructs of monoclonal antibody CC49: generation, characterization, pharmacokinetics and biodistribu-tion analysis. Nucl. Med. Biol. (1999) 26:27–34.
  • ARANO Y, FUJIOKA Y, AKIZAWA H et al.: Chemical design of radiolabeled antibody fragments for low renal radioactivity levels. Cancer Res. (1999)59:128–134.
  • ROBERT B, DORVILLIUS M, BUCHEGGER F et al.: Tumortargeting with newly designed biparatopic antibodies directed against two different epitopes of the carcinoembryonic antigen (CEA). Int. J. Cancer (1999) 81:285–291.
  • SEGAL DM, WEINER GJ, WEINER LM: Bispecific antibodies in cancer therapy. Curr. Opin. Immunol. (1999) 11:558–562.
  • DENARDO SJ, DENARDO GL, BRUSH J, CARTER P: Phagelibrary-derived human anti-TETA and anti-DOTA ScEv for pretargeting RIT. Hybridoma (1999) 18:13–21.
  • KRAEBER-BODERE F, FAIBRE-CHAUVET A, SAI-MAUREL Cet al.: Bispecific antibody and bivalent hapten radioim-munotherapy in CEA-producing medullary thyroid cancer xenograft. J. Nucl. Med. (1999) 40:198–204.
  • BAUER S, RENNER C, JUWANA JP et al.: Immunotherapyof human tumors with T-cell-activating bispecific antibodies: stimulation of cytotoxic pathways in vivo. Cancer Res. (1999) 59:1961–1965.
  • MANZKE O, BERTHOLD F, HUEBEL K, TESCH H, DIEHL V,BOHLEN H: CD3xCD19 bispecific antibodies and CD28 bivalent antibodies enhance T-cell reactivity against autologous leukemic cells in pediatric B-ALL bone marrow. Int. J. Cancer (1999) 80:715–722.
  • MCCALL AM, ADAMS GP, AMOROSO AR et al.: Isolationand characterization of an anti-CD16 single-chain Fv fragment and construction of an anti-HER2/neu/ anti-CD16 bispecific scEv that triggers CD16-dependent tumor cytolysis. Mol. Immunol. (1999) 36:433–445.
  • PULLARKAT V, DEO Y, LINK J et al.: A Phase I study of aHER2/neu bispecific antibody with granulocyte-colony-stimulating factor in patients with metastatic breast cancer that overexpresses HER2/neu. Cancer Immunol. Immunother. (1999) 48:9–21.
  • CURIEL DT: Strategies to adapt adenoviral vectors fortargeted delivery. Ann. NY Acad. Sci . (1999) 886:158–171.
  • BARTLETT JS, KLEINSCHMIDT J, BOUCHER RC, SAMULSKIRJ: Targeted adeno-associated virus vector transduc-tion of nonpermissive cells mediated by a bispecific F(ab'gamma)2 antibody. Nature Biotechnol. (1999) 17:181–186.
  • CHAUDRI ZN, BARTLET-JONES M, PANAYOTOU G et al.:Dual specificity antibodies using a double-stranded oligonucleotide bridge. FESS Lea. (1999) 450:23–26.
  • MANZKE O, FITZGERALD KJ, HOLLIGER P et al.: CD3X anti-nitrophenyl bispecific diabodies: universal irnmunotherapeutic tools for retargeting T cells to tumors. Int. J. Cancer (1999) 82:700–708.
  • HOLLIGER P, MANZKE O, SPAN M et al.: Carcinoembry-onic antigen (CEA)-specific T-cell activation in colon carcinoma induced by anti-CD3 x anti-CEA bispecific diabodies and B7 x anti-CEA bispecific fusion proteins. Cancer Res. (1999) 59:2909–2916.
  • ARNDT MA, KRAUSS J, KIPRIYANOV SM, PFREUNDSCHUH M, LITTLE M: A bispecific diabody that mediates natural killer cell cytotoxicity against xenotransplantated human Hodgkin's tumors. Blood (1999) 94:2562–2568.
  • KIPRIYANOV SM, MOLDENHAUER G, SCHUHMACHER J et al.: Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics. J. Mol. Biol. (1999) 293:41–56.
  • ••A very promising molecular design for immunotherapy,extending the diabody concept into a tetrabody format for T-cell recruitment and retaining high target avidity.
  • KREITMAN RJ: Immunotoxins in cancer therapy. Curr. Opin. Immunol. (1999) 11:570–578.
  • BIRCHLER M, VITT F, ZARDI L, SPIESS B, NERI D: Selective targeting and photocoagulation of ocular angiogene-sis mediated by a phage-derived human antibody fragment. Nature Biotechnol. (1999) 17:984–988.
  • KNOX SJ, GORIS ML, TEMPERO M et al.: Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer. Clin. Cancer Res. (2000) 6:406–414.
  • SHABAT D, RADER C, LIST B, LERNER RA, BARBAS CF 3RD: Multiple event activation of a generic prodrug trigger by antibody catalysis. Proc. Natl. Acad. Sci. USA (1999) 96:6925–6930.
  • ••Possibly a very useful adaptation to ADEPT strategy; this is abroadly applicable drug-masking chemistry that operates in conjunction with a wide range of drugs because it is compatible with virtually any heteroatom. The reaction cascade is not catalysed by any known natural enzyme and can be applied to release of anticancer drugs doxorubicin and camptothecin.
  • LEE HJ, ENGELHARDT B, LESLEY J, BICKEL U, PARDRIDGE WM: Targeting rat anti-mouse transferrin receptor monoclonal antibodies through blood-brain barrier in mouse. J. Pharmacol. Exp. Ther. (2000) 292:1048–1052.
  • KURIHARA A, DEGUCHI Y, PARDRIDGE WM: Epidermal growth factor radiopharmaceuticals: 111In chelation, conjugation to a blood-brain barrier delivery vector via a biotin-polyethylene linker, pharmacokinetics and in vivo imaging of experimental brain tumors. Bioconjug. Chem. (1999) 10:502–511.
  • HUDSON AJ, NORMAND N, ACKROYD J, AKHTAR S: Cellular delivery of hammerhead ribozymes conjugated to a transferrin receptor antibody. Int. J. Pharm. (1999) 182:49–58.
  • MARTIN F, NEIL S, KUPSCH J, MAURICE M, COSSET F,COLLINS M: Retrovirus targeting by tropism restriction to melanoma cells. J Virol. (1999) 73:6923–6929.
  • POUL MA, MARKS JD: Targeted gene delivery to mammalian cells by filamentous bacteriophage. J. Mol. Biol. (1999) 288:203–211.
  • ••Phage capable of binding mammalian cells expressing thegrowth factor receptor ErbB2 and undergoing receptor-mediated endocytosis were isolated by selection of a phage antibody library on breast tumour cells and recovery of infectious phage from within the cell.
  • PAGNAN G, STUART DD, PASTORINO F et al.: Delivery of c-myb antisense oligodeoxynucleotides to human neuroblastoma cells via disialoganglioside GD(2)-targeted irnmunoliposomes: antitumor effects. J. Natl. Cancer Inst. (2000) 92:253–261.
  • TSENG YL, HONG RL, TAO MH, CHANG FH: Sterically stabilized anti-idiotype irnmunoliposomes improve the therapeutic efficacy of doxorubicin in a murine B-cell lymphoma model. Int]. Cancer(1999) 80:723–730.
  • DE INES C, COCHLOVIUS B, SCHMIDT S et al.: Apoptosis of a human melanoma cell line specifically induced by membrane-bound single-chain antibodies. J. Immunol. (1999) 163:3948–3956.
  • ZHAO L, RAT SK, GROSMAIRE LS, LEDBETTER JA, FELL HP:Construction, expression and characterization of anticarcinoma sFy fused to IL-2 or GM-CSF. J. Hemato-ther. Stem Cell Res. (1999) 8:393–399.
  • PENG LS, PENICHET ML, MORRISON SL: A single-chain IL-12 IgG3 antibody fusion protein retains antibody specificity and IL-12 bioactivity and demonstrates antitumor activity. J. Immunol. (1999) 163:250–258.
  • LUNDE E, MUNTHE LA, VABO A, SANDLIE I, BOGEN B: Antibodies engineered with IgD specificity efficiently deliver integrated T-cell epitopes for antigen presenta-tion by B cells. Nature Biotechnol. (1999) 17:670–675.
  • TIMMERMAN JM, LEVY R: Dendritic cell vaccines for cancer immunotherapy. Ann. Rev. Med. (1999) 50:507–529.
  • SOTOMAYOR EM, BORRELLO I, TUBB E et al.: Conver-sion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40. Nature Med. (1999) 5:780–787.
  • BIRAGYN A, TANI K, GRIMM MC, WEEKS S, KWAK LW: Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity. Nature Biotechnol. (1999) 17:253–257.
  • FOON KA, JOHN WJ, CHAKRABORTY M et al.: Clinical and immune responses in resected colon cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen. J. Clin. Oncol. (1999) 17:2889–2895.
  • TAMURA M, MILENIC DE, IWAHASHI M, PADLAN E, SCHLOM J, KASHMIRI SV: Structural correlates of an anticarcinoma antibody: identification of specificity-determining residues (SDRs) and development of a minimally immunogenic antibody variant by retention of SDRs only. J. Immunol. (2000) 164:1432–1441.
  • BEIBOER SH, REURS A, ROOVERS RC et al Guided selection of a pan carcinoma specific antibody reveals similar binding characteristics yet structural divergence between the original murine antibody and its human equivalent. J. Mol Biol. (2000) 296:833–849
  • VAN DEN ELSEN JM, KUNTZ DA, HOEDEMAEKER FJ, ROSEDR: Antibody C219 recognizes an alpha-helical epitope on P-g,lycoprotein. Proc. Natl. Acad. Sci. USA (1999) 96:13679–13684.
  • NGUYEN VK, HAMERS R, WYNS L, MUYLDERMANS S: Camel heavy-chain antibodies: diverse germline V(H)H and specific mechanisms enlarge the antigen-binding repertoire. EMBO J. (2000) 19:921–930.
  • NUTTALL SD, ROUSCH MJM, IRVING RA, HUFTON SE, HOOGENBOOM HR, HUDSON PJ: Design and expres-sion of soluble CTIA-4 Variable domain as a scaffold for the display of functional polypeptides. Proteins (1999) 36:217–227.
  • WILLUDA J, HONEGGER A, WAIBEL R et al.: High thermalstability is essential for tumor targeting of antibody fragments: engineering of a humanized anti-epithelial glycoprotein-2 (epithelial cell adhesion molecule) single-chain Fv fragment. Cancer Res. (1999) 59:5758–5767.
  • JAGER M, PLUCKTHUN A: Folding and assembly of anantibody Fv fragment, a heterodimer stabilized by antigen. J. Mol. Biol. (1999) 285:2005–2019.
  • MAO S, GAO C, LO CH, WIRSCHING P, WONG CH, JANDAKD: Phage-display library selection of high-affinity human single-chain antibodies to tumor-associated carbohydrate antigens sialyl Lewisx and Lewisx. Proc. Natl. Acad. Sci. USA (1999) 96:6953–6958.
  • JUNG S, HONEGGER A, PLUCKTHUN A: Selection for improved protein stability by phage display. J. Mol. Biol. (1999) 294:163–180.
  • WORN A, AUF DER MAUR A, ESCHER D et al.: Correlationbetween in vitro stability and in vivo performance of anti-GCN4 intrabodies as cytoplasmic inhibitors. J. Biol. Chem. (2000) 275:2795–2803.
  • MARIN M, PELEGRIN-ZURILLA M, BACHRACH E et al.:Antiviral activity of an intracellularly expressed single-chain antibody fragment directed against the murine leukemia virus capsid protein. Human Gene. Ther. (2000) 11:389–401.
  • HOOGENBOOM HR, LUTGERINK JT, PELSERS M et al.:Selection-dominant and nonaccessible epitopes on cell-surface receptors revealed by cell-panning with a large phage antibody library. Eur. J. Biochem. (1999) 260:774–784.
  • KNAPPIK A, GE L, HONEGGER A et al.: Fully synthetichuman combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides. J. Mol. Biol. (2000) 296:57–86.
  • LITTLE M, WELSCHOF M, BRAUNAGEL M et al.: Genera-tion of a large complex antibody library from multiple donors. J. Immunol. Methods (1999) 231:3–9.
  • SBLATTERO D, BRADBURY A: Exploiting recombina-tion in single bacteria to make large phage antibody libraries. Nature Biotechnol (2000) 18:75–80.
  • SCHAFFITZEL C, HANES J, JERMUTUS L, PLUCKTHUN A:Ribosome display: an in vitro method for selection and evolution of antibodies from libraries. J. Immunol. Methods (1999) 231:119–135.
  • HE M, MENGES M, GROVES MA et al.: Selection of ahuman anti-progesterone antibody fragment from a transgenic mouse library by ARM ribosome display. J. Immunol. Methods. (1999) 231:105–117.
  • DAUGHERTY PS, CHEN G, IVERSON BL, GEORGIOU G:Quantitative analysis of the effect of the mutation frequency on the affinity maturation of single chain Fv antibodies. Proc. Natl. Acad . Sci. USA (2000) 97:2029–2034.
  • DAUGHERTY PS, OLSEN MJ, IVERSON BL, GEORGIOU G.Development of an optimized expression system for the screening of antibody libraries displayed on the Escherichia coli surface. Protein Eng. (1999) 12:613–621.
  • VAN ANTWERP JJ, WITTRUP KB: Fine affinity discrimi-nation by yeast surface display and flow cytometry. Biotechnol. Prog. (2000) 16:31–37.
  • JUNG S, ARNDT KM, MULLER KM, PLUCKTHUN A: Selectively infective phage (SIP) technology: scope and limitations. J. Immunol. Methods (1999) 231:93–104.
  • YANG XD, JIA XC, CORVALAN JR, WANG P, DAVIS CG,JAKOBOVITS A: Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res. (1999) 59:1236–1243.
  • GREEN LL: Antibody engineering via genetic engineering of the mouse: Xenomouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies. J. Immunol. Methods (1999) 231:11–24.
  • BORREBAECK CAK: Human monoclonal antibodies: The emperor's new clothes? Nature Biotech. (1999) 17:621.

Websites

  • http://www.mgen.uni-heidelberg.de/SD/SDscFvSite.html Antibody structures.
  • http://www.path.cam.ac.uk/--mrc7/humanisation/antibodi es.html List of humanised antibodies
  • http://www.mrc-cpe.cam.ac.uk/imt-doc Vbase; human antibody sequences
  • http://www.antibodyresource.com USA links and others.
  • http://www.morphosys.com/ HuCAL scFv library.
  • http://www.catplc.co.uk CAT scFv library.
  • http://www.dyax.com/ Dyax Fab library.
  • http://www.bioinvent.com/ BioInvent Ab library.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.